Comparative in vivo dose-dependent activity of caspofungin and anidulafungin against echinocandin-susceptible and -resistant Aspergillus fumigatus

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 6, 2011, Pages 1324-1331

  Lewis, Russell E ^a,b   Liao, Guangling ^a   Hou, Jingguo ^a   Prince, Randall A ^a,b   Kontoyiannis, Dimitrios P ^a,b  

^a UNIVERSITY OF HOUSTON   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Aspergillosis; Echinocandins; Pharmacodynamics; Resistance

Indexed keywords

ANIDULAFUNGIN; CASPOFUNGIN; ECHINOCANDIN; FUNGAL PROTEIN; PROLINE; PROTEIN FKS1; PROTEIN FKS1P; SERINE; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANTIFUNGAL ACTIVITY; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; ASPERGILLUS FUMIGATUS; CONTROLLED STUDY; DRUG EFFICACY; FUNGAL GENE; FUNGAL STRAIN; FUNGAL VIRULENCE; GENE MUTATION; HISTOPATHOLOGY; IN VIVO STUDY; LUNG; LUNG ASPERGILLOSIS; MOUSE; NEUTROPENIA; NONHUMAN; QUANTITATIVE ASSAY; REAL TIME POLYMERASE CHAIN REACTION; SURVIVAL TIME;

ANIMALS; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, FUNGAL; ECHINOCANDINS; MICE; MICE, INBRED BALB C; TREATMENT OUTCOME;

EID: 79956035598     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr142     Document Type: Article

References (39)

1. Pappas PG, Kauffman CA, Andes D et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 503-35.
2. Walsh TJ, Anaissie EJ, Denning DW et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46: 327-60.
3. Denning DW. Echinocandin antifungal drugs. Lancet 2003; 362: 1142-51.
4. Andes D, Diekema DJ, Pfaller MA et al. In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. Antimicrob Agents Chemother 2010; 54: 2497-506.
5. Betts RF, Nucci M, Talwar D et al. A multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis. Clin Infect Dis 2009; 48: 1676-84.
6. Pappas PG, Rotstein CM, Betts RF et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007; 45: 883-93.
7. Lewis RE, Albert ND, Kontoyiannis DP. Comparison of the dose-dependent activity and paradoxical effect of caspofungin and micafungin in a neutropenic murine model of invasive pulmonary aspergillosis. J Antimicrob Chemother 2008; 61: 1140-4.
8. Wiederhold NP, Kontoyiannis DP, Chi J et al. Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity. J Infect Dis 2004; 190: 1464-71.
9. Wiederhold NP. Paradoxical echinocandin activity: a limited in vitro phenomenon? Med Mycol 2009; 47 Suppl 1: S369-75.
10. Wheeler RT, Fink GR. A drug-sensitive genetic network masks fungi from the immune system. PLoS Pathog 2006; 2: e35.
11. Wheeler RT, Kombe D, Agarwala SD et al. Dynamic, morphotype-specific Candida albicans β-glucan exposure during infection and drug treatment. PLoS Pathog 2008; 4: e1000227.
12. Hohl TM, Feldmesser M, Perlin DS et al. Caspofungin modulates inflammatory responses to Aspergillus fumigatus through stage-specific effects on fungal β-glucan exposure. J Infect Dis 2008; 198: 176-85.
13. Wiederhold NP. Attenuation of echinocandin activity at elevated concentrations: a review of the paradoxical effect. Curr Opin Infect Dis 2007; 20: 574-8.
14. Walker LA, Munro CA, de Bruijn I et al. Stimulation of chitin synthesis rescues Candida albicans from echinocandins. PLoS Pathog 2008; 4: e1000040.
15. Rocha EM, Garcia-Effron G, Park S et al. A Ser678Pro substitution in Fks1p confers resistance to echinocandin drugs in Aspergillus fumigatus. Antimicrob Agents Chemother 2007; 51: 4174-6.
16. Perlin DS. Resistance to echinocandin-class antifungal drugs. Drug Resist Updat 2007; 10: 121-30.
17. Arendrup MC, Garcia-Effron G, Buzina W et al. Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing. Antimicrob Agents Chemother 2009; 53: 1185-93.
18. Pfaller MA, Boyken L, Hollis RJ et al. In vitro susceptibility of clinical isolates of Aspergillus spp. to anidulafungin, caspofungin, and micafungin: a head-to-head comparison using the CLSI M38-A2 broth microdilution method. J Clin Microbiol 2009; 47: 3323-5.
19. Lewis RE, Wiederhold NP. Murine model of invasive aspergillosis. Methods Mol Med 2005; 118: 129-42.
20. Bowman JC, Abruzzo GK, Anderson JW et al. Quantitative PCR assay to measure Aspergillus fumigatus burden in a murine model of disseminated aspergillosis: demonstration of efficacy of caspofungin acetate. Antimicrob Agents Chemother 2001; 45: 3474-81.
21. Wiederhold NP, Tam VH, Chi J et al. Pharmacodynamic activity of amphotericin B deoxycholate is associated with peak plasma concentrations in a neutropenic murine model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother 2006; 50: 469-73.
22. Andes D, Diekema DJ, Pfaller MA et al. In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. Antimicrob Agents Chemother 2008; 52: 539-50.
23. Park S, Kelly R, Kahn JN et al. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob Agents Chemother 2005; 49: 3264-73.
24. Garcia-Effron G, Kontoyiannis DP, Lewis RE et al. Caspofungin-resistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignancies. Antimicrob Agents Chemother 2008; 52: 4181-3.
25. Garcia-Effron G, Lee S, Park S et al. Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-β-D-glucan synthase: implication for the existing susceptibility breakpoint. Antimicrob Agents Chemother 2009; 53: 3690-9.
26. Kurtz MB, Abruzzo G, Flattery A et al. Characterization of echinocandin-resistant mutants of Candida albicans: genetic, biochemical, and virulence studies. Infection Immunity 1996; 64: 3244-51.
27. Anderson JB. Evolution of antifungal-drug resistance: mechanisms and pathogen fitness. Nat Rev Microbiol 2005; 3: 547-56.
28. Arendrup MC, Perkhofer S, Howard SJ et al. Establishing in vitro-in vivo correlations for Aspergillus fumigatus: the challenge of azoles versus echinocandins. Antimicrob Agents Chemother 2008; 52: 3504-11.
29. Leventakos K, Lewis RE, Kontoyiannis DP. Effect of low and high dose of caspofungin (CAS) in a neutropenic and a steroid treated murine model of pulmonary mucormycosis. In: Abstracts of the Forty-ninth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 2009. Abstract M-1690. American Society for Microbiology, Washington, DC, USA.
30. Ibrahim AS, Bowman JC, Avanessian V et al. Caspofungin inhibits Rhizopus oryzae 1,3-β-D-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis. Antimicrob Agents Chemother 2005; 49: 721-7.
31. Ibrahim AS, Gebremariam T, Fu Y et al. Combination echinocandin-polyene treatment of murine mucormycosis. Antimicrob Agents Chemother 2008; 52: 1556-8.
32. Lamaris GA, Lewis RE, Chamilos G et al. Caspofungin-mediated β-glucan unmasking and enhancement of human polymorphonuclear neutrophil activity against Aspergillus and non-Aspergillus hyphae. J Infect Dis 2008; 198: 186-92.
33. Katiyar SK, Edlind TD. Role for Fks1 in the intrinsic echinocandin resistance of Fusarium solani as evidenced by hybrid expression in Saccharomyces cerevisiae. Antimicrob Agents Chemother 2009; 53: 1772-8.
34. Garcia-Effron G, Park S, Perlin DS. Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. Antimicrob Agents Chemother 2009; 53: 112-22.
35. Chamilos G, Lewis RE, Albert N et al. Paradoxical effect of echinocandins across Candida species in vitro: evidence for echinocandin-specific and Candida species-related differences. Antimicrob Agents Chemother 2007; 51: 2257-9.
36. Wiederhold NP, Wickes BL, Patterson TF. Increased gene expression of mitogen-activated protein kinase A is associated with attenuated caspofungin activity in Aspergillus fumigatus. In: Abstracts of the Forty-sixth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 2006. Abstract M-0364. American Society for Microbiology, Washington, DC, USA.
37. Mouton JW, Theuretzbacher U, Craig WA et al. Tissue concentrations: do we ever learn? J Antimicrob Chemother 2008; 61: 235-7.
38. Stone JA, Xu X, Winchell GA et al. Disposition of caspofungin: role of distribution in determining pharmacokinetics in plasma. Antimicrob Agents Chemother 2004; 48: 815-23.
39. Balloy V, Huerre M, Latge JP et al. Differences in patterns of infection and inflammation for corticosteroid treatment and chemotherapy in experimental invasive pulmonary aspergillosis. Infect Immun 2005; 73: 494-503.